Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies

Giandomenico Roviello, Kristian Shtembari, Ismaela Anna Vascotto, Martina Izzi, Chiara Calandrelli, Silvia Mancini, Marinella Micol Mela, Virginia Rossi, Roberta Giorgione, Serena Pillozzi, Lorenzo Antonuzzo

Open source

DOI: 10.6084/m9.figshare.34933165.v1
Published: 2026
Container: Not recorded
Publisher: Taylor & Francis
Open access: yes

Credibility signals

limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.6084/m9.figshare.34933165.v1,
  title = {Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies},
  author = {Giandomenico Roviello and Kristian Shtembari and Ismaela Anna Vascotto and Martina Izzi and Chiara Calandrelli and Silvia Mancini and Marinella Micol Mela and Virginia Rossi and Roberta Giorgione and Serena Pillozzi and Lorenzo Antonuzzo},
  year = {2026},
  doi = {10.6084/m9.figshare.34933165.v1},
  url = {https://doi.org/10.6084/m9.figshare.34933165.v1}
}

RIS

TY  - JOUR
TI  - Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies
AU  - Giandomenico Roviello
AU  - Kristian Shtembari
AU  - Ismaela Anna Vascotto
AU  - Martina Izzi
AU  - Chiara Calandrelli
AU  - Silvia Mancini
AU  - Marinella Micol Mela
AU  - Virginia Rossi
AU  - Roberta Giorgione
AU  - Serena Pillozzi
AU  - Lorenzo Antonuzzo
PY  - 2026
DO  - 10.6084/m9.figshare.34933165.v1
UR  - https://doi.org/10.6084/m9.figshare.34933165.v1
ER  -

APA

Roviello, G., Shtembari, K., Vascotto, I. A., Izzi, M., Calandrelli, C., Mancini, S., Mela, M. M., Rossi, V., Giorgione, R., Pillozzi, S., & Antonuzzo, L. (2026). Trastuzumab deruxtecan in HER2-expressing urothelial carcinoma: current evidence, biomarker challenges, and future therapeutic strategies. https://doi.org/10.6084/m9.figshare.34933165.v1

Source records

datacite · retrieved 2026-11-10T11:28:23.159Z